scPharmaceuticals

SCPH

Börsenwert 304 Mio. $

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving sp.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of scPharmaceuticals Inc. (NasdaqGS: SCPH) to MannKind Corporation (NasdaqGM: MNKD). Under the terms of the proposed transaction, shareholders of scPharmaceuticals would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specifi.

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

MONSEY, N.Y., Aug. 25, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. (Nasdaq: SCPH) (“SCPH”) to MannKind Corporation (“MannKind”) for $5.35 per share in cash, plus one non-tradable contingent value right (“CVR”) per share offering milestone-based payments of up to $1.00 per share.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of scPharmaceuticals Inc. (NASDAQ: SCPH) to MannKind Corporation is fair to scPharmaceuticals shareholders. Under the terms of the proposed transaction, scPharmaceuticals shareholders would receive a cash payment of $5.35 per share plus one non-tradable contingent value right (CVR) per share payable upon achieving specific regulatory and net sales milestones worth up to $1.00 per CVR in c.

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating scPharmaceuticals (NASDAQ: SCPH) for possible breaches of fiduciary duty and other violations of law in its transaction with MannKind. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. Shareholders of scPharmaceuticals will receive $5.35 per share in cash plus contingent value rights worth up to $1.0.

DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals.

BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from the United States Patent and Trademark Office (USPTO) for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation.

scPharmaceuticals Inc. (NASDAQ:SCPH ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants John Mohr - Senior Vice President of Clinical Development & Medical Affairs John H. Tucker - President, CEO, Principal Executive Officer & Director Rachael Nokes - Chief Financial Officer Steve C.

scPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.44 per share a year ago.